Neumann Capital Management LLC Sells 1,500 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Neumann Capital Management LLC cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% in the third quarter, Holdings Channel reports. The fund owned 39,790 shares of the biopharmaceutical company’s stock after selling 1,500 shares during the period. Gilead Sciences comprises approximately 1.1% of Neumann Capital Management LLC’s holdings, making the stock its 22nd biggest position. Neumann Capital Management LLC’s holdings in Gilead Sciences were worth $3,336,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Manning & Napier Advisors LLC bought a new position in shares of Gilead Sciences in the second quarter valued at about $25,328,000. Legal & General Group Plc lifted its position in shares of Gilead Sciences by 0.8% during the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after purchasing an additional 93,068 shares in the last quarter. IRON Financial LLC bought a new stake in shares of Gilead Sciences during the third quarter valued at approximately $830,000. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Gilead Sciences by 13.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock valued at $19,630,000 after purchasing an additional 33,162 shares in the last quarter. Finally, Cetera Investment Advisers raised its position in Gilead Sciences by 127.6% in the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock worth $15,668,000 after purchasing an additional 119,909 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Piper Sandler lifted their target price on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Sanford C. Bernstein began coverage on Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price objective for the company. Evercore ISI raised shares of Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Maxim Group cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Finally, Citigroup began coverage on shares of Gilead Sciences in a report on Thursday. They issued a “buy” rating and a $125.00 price objective on the stock. Eleven analysts have rated the stock with a hold rating, ten have issued a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $93.10.

Gilead Sciences Trading Down 0.6 %

Shares of NASDAQ:GILD opened at $92.11 on Friday. The firm has a market cap of $114.79 billion, a price-to-earnings ratio of 1,023.44, a PEG ratio of 2.85 and a beta of 0.17. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company’s fifty day simple moving average is $86.22 and its 200 day simple moving average is $75.69. The company has a quick ratio of 0.82, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the business posted $2.29 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post 4.39 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.34%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 3,422.22%.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. This represents a 1.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This represents a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 56,947 shares of company stock valued at $4,968,674 in the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.